Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001

被引：0

作者：

Ohe, Y. ^{[1
]}

Subbiah, V. ^{[2
]}

Sukrithan, V. ^{[3
,4
]}

Robinson, B. ^{[5
]}

Deschler-Baier, B. ^{[6
]}

Iwasa, T. ^{[7
]}

Ohashi, K. ^{[8
]}

Goto, K. ^{[9
]}

Nishio, M. ^{[10
]}

Satouchi, M. ^{[11
]}

Nakamura, K. ^{[12
]}

Ashiguchi, S. ^{[12
]}

Lin, Y. ^{[13
]}

Szymczak, S. ^{[13
]}

Drilon, A. ^{[14
]}

机构：

[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

[3] Ohio State Univ, Div Med Oncol, Columbus, OH USA

[4] Arthur G James Canc Ctr, Columbus, OH USA

[5] Royal North Shore Hosp, Dept Endocrinol, St Leonards, NSW, Australia

[6] Univ Hosp Wurzburg, Comprehens Canc Ctr, Wurzburg, Germany

[7] Kindai Univ, Dept Med Oncol, Fac Med Dept, Osaka, Japan

[8] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[9] Natl Canc Ctr East, Dept Thorac Oncol, Chiba, Japan

[10] Canc Inst Hosp JFCR, Dept Thorac Med Oncol, Tokyo, Japan

[11] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Japan

[12] Eli Lilly Japan KK, Japan Drug Dev & Med Affairs, Kobe, Japan

[13] Eli Lilly & Co, Indianapolis, IN USA

[14] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

来源：

关键词：

D O I：

10.1016/j.annonc.2024.07.652

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O14-2

引用

页码：S1322 / S1322

页数：1